I claim:

1. A method for inducing an immune response against transformed, infected or diseased tissue comprising

contacting the blood of a patient in need thereof with an effective amount of a molecule binding to soluble cytokine receptor molecules, wherein the cytokine is selected from the group consisting of GM-CSF, erythropoietin, thrombopoetin, G-CSF, M-CSF and SCF, wherein binding of the molecule prevents the soluble cytokine receptor from binding to the cytokine, until the transformed, infected, or diseased tissue is reduced in amount.

- 2. The method of claim 1 wherein the tissue is a solid tumor.
- 3. The method of claim 1 wherein the disease is a viral or parasitic disease causing immunosuppression.
- 4. The method of claim 1 wherein the molecule is an antibody to the soluble cytokine receptor.
- 5. The method of claim 1 further comprising treating the tissue with an agent selected from the group consisting of anti-angiogenic compounds, procoagulant compounds, cytokines, chemotherapeutic agents, and radiation.
- 6. The method of claim 1 further comprising selectively removing soluble cytokine receptor molecules.
- 7. The method of claim 1 wherein the soluble cytokine receptor molecules are selected from the group consisting of soluble tissue necrosis factor receptor-1 ("sTNFR-1") and soluble tissue necrosis factor receptor-2 ("sTNFR-2").
- 8. The method of claim 7 wherein the cytokine receptor molecules are removed by binding to the cytokine or to an antibody or antibody fragment immunoreactive with the cytokine receptor molecules.
- 9. The method of claim 8 wherein the cytokine or antibody or antibody fragments are immobilized in a filter or column through which the patient's blood or plasma is circulated prior to being returned to the patient.

Sul



The method of claim 4 wherein the antibody is humanized.

A composition for inducing an immune response against transformed, infected or diseased tissue comprising

molecules binding to soluble cytokine receptor molecules, wherein the cytokine is selected from the group consisting of GM-CSF, erythropoietin, thrombopoetin, G-CSF, M-CSF and SCF, wherein binding of the molecule prevents the soluble cytokine receptor from binding to the cytokine, in an amount effective to reduce the amount of transformed, infected, or diseased tissue, wherein the molecules are in a pharmaceutically acceptable, endotoxin free carrier or immobilized in a sterile endotoxin free extracorporeal device.

- The composition of claim 11 wherein the device is an absorbent column 12. selectively removing specific cytokine or cellular inhibitors from the blood.
- The composition of claim 11 wherein the molecules are antibodies. 13.
- 14. The composition of claim 13 wherein the antibodies are humanized.
- The composition of claim 13 wherein the antibodies are fragments 15. including the epitope binding regions.
- The composition of claim 11 wherein the cytokine or cellular inhibitors 16. are selected from the group consisting of soluble tissue necrosis factor receptor-1 ("sTNFR-1") and soluble tissue necrosis factor receptor-2 ("sTNFR-2").